
    
      This trial is a prospective, randomized, placebo-controlled, double-blind pivotal study, with
      an open-label extension. The study will include 4 sites and multiple investigators. A total
      of 100 men with at least a 6-month history of ED and who have responded to PDE5 inhibitors
      will be enrolled. The trial comprises two arms to achieve equal characteristics, where
      patients are randomly assigned to active treatment or sham treatment.

      All patients on active treatment will receive LI-ESWT treatment using the Dornier Aries 2.
      Patients assigned to the placebo group will receive the Dornier Aries 2 treatment using a
      sham applicator. The time between two treatments is 6-7 days to allow for angiogenesis and
      perfusion improvements to occur. The subjects' duration of participation will be a total of
      34 weeks Subjects will also be asked to maintain their current level of sexual activity while
      participating in the study.
    
  